Tech entrepreneur David Apple has joined the CMTA Board of Directors, bringing a strong business background and a personal commitment to advancing treatments and cures for CMT. Apple’s involvement reflects CMTA’s continued focus on leadership that combines professional expertise with lived experience in the CMT community.
CMTA Funds Preclinical Work on Modulating Unfolded Protein Response in CMT1B Mice
CMTA has funded a preclinical study exploring whether modulating the unfolded protein response (UPR) can address disease mechanisms in CMT1B. The project will evaluate activation of the ATF6 pathway in CMT1B mouse models to determine whether this approach can reduce cellular stress linked to myelin dysfunction and inform future therapeutic development.
CMTA Adds Drug Development Expert Martine Garnier to STAR Advisory Board
CMTA appoints drug development expert Martine Garnier, PhD, EMBA, to its STAR Advisory Board, strengthening its translational and therapeutic development expertise. Garnier brings more than two decades of experience in drug discovery and clinical development across academia, biotech, and pharmaceutical organizations.
Skilled Nonprofit Fundraiser Craig Zeltsar Brings Expertise to CMTA Board of Directors
CMTA has welcomed Craig Zeltsar to its Board of Directors, bringing decades of nonprofit fundraising and membership experience. Zeltsar’s background in donor-centered strategy, combined with his personal connection to the CMT community, strengthens CMTA’s leadership as it advances research and patient support.
Shift Pharmaceuticals, Charcot-Marie-Tooth Association Partner on ASO Treatment for CMT1A
CMTA has partnered with Shift Pharmaceuticals to evaluate an antisense oligonucleotide (ASO) for the treatment of CMT1A. The collaboration will use CMTA-STAR preclinical testing capabilities to assess the therapeutic potential of an ASO designed to reduce PMP22 overexpression and support advancement toward clinical trials.
CMTA Kicks Off CMT Awareness Month 2022
CMTA kicks off CMT Awareness Month 2022 with a month-long series of educational and community-driven activities designed to increase understanding of CMT. The campaign highlights people living with CMT and encourages public participation through digital engagement and awareness efforts.
CMTA Welcomes Software Entrepreneur Jon Pastor to Board of Directors
CMTA has appointed software entrepreneur Jon Pastor to its Board of Directors, adding leadership experience in technology and operations. Pastor brings a strong business background and a personal connection to the CMT community, supporting CMTA’s research and patient-focused mission.
CMTA Appoints Katherine Forsey, PhD, Chief Research Officer
CMTA has appointed Katherine Forsey, PhD, as its first Chief Research Officer, reflecting the continued growth of its Strategy To Accelerate Research (CMTA-STAR). Forsey brings experience across research, program leadership, and science communication to support CMTA’s expanding global research portfolio.
The Charcot-Marie-Tooth Association Earns a Perfect Rating From Charity Navigator
CMTA has earned a perfect score from Charity Navigator, receiving a four-star rating for financial health, accountability, and transparency. The recognition places CMTA among a small group of health-related nonprofits meeting Charity Navigator’s highest standards for responsible stewardship.
CMTA | STAR Awards $354,826 For Charcot-Marie-Tooth Clinical Trial
CMTA-STAR has awarded $354,826 to support a clinical trial evaluating L-serine in patients with Hereditary Sensory Neuropathy 1, a rare form of CMT. Led by Dr. Mary Reilly at University College London, the study will assess disease progression using MRI muscle fat fraction as a primary outcome measure, advancing clinical trial readiness for inherited neuropathies.
